BlackRock
CGEM icon

BlackRock’s Cullinan Oncology CGEM Stock Holding History

BlackRock’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.3M Buy
5,232,766
+782,800
+18% +$11.6M ﹤0.01% 2252
2026
Q1 		$63.2M Buy
4,449,966
+49,670
+1% +$638K ﹤0.01% 2363
2025
Q4 		$45.5M Buy
4,400,296
+230,334
+6% +$2.08M ﹤0.01% 2580
2025
Q3 		$24.7M Sell
4,169,962
-47,971
-1% -$351K ﹤0.01% 2958
2025
Q2 		$31.8M Sell
4,217,933
-2,929
-0.1% -$23.5K ﹤0.01% 2756
2025
Q1 		$32M Sell
4,220,862
-150,163
-3% -$1.44M ﹤0.01% 2642
2024
Q4 		$53.2M Buy
4,371,025
+32,300
+0.7% +$464K ﹤0.01% 2416
2024
Q3 		$72.6M Buy
4,338,725
+788,518
+22% +$14M ﹤0.01% 2260
2024
Q2 		$61.9M Buy
3,550,207
+1,121,214
+46% +$23.9M ﹤0.01% 2293
2024
Q1 		$41.4M Sell
2,428,993
-33,281
-1% -$514K ﹤0.01% 2551
2023
Q4 		$25.1M Buy
2,462,274
+225,989
+10% +$2M ﹤0.01% 2880
2023
Q3 		$20.2M Buy
2,236,285
+132,216
+6% +$1.38M ﹤0.01% 2934
2023
Q2 		$22.6M Sell
2,104,069
-151,528
-7% -$1.61M ﹤0.01% 2954
2023
Q1 		$23.1M Sell
2,255,597
-250,618
-10% -$2.76M ﹤0.01% 2905
2022
Q4 		$26.4M Buy
2,506,215
+131,390
+6% +$1.6M ﹤0.01% 2879
2022
Q3 		$30.4M Buy
2,374,825
+143,098
+6% +$1.93M ﹤0.01% 2788
2022
Q2 		$28.6M Buy
2,231,727
+405,558
+22% +$4.6M ﹤0.01% 2881
2022
Q1 		$19.1M Sell
1,826,169
-12,943
-0.7% -$175K ﹤0.01% 3197
2021
Q4 		$28.4M Buy
1,839,112
+209,518
+13% +$4.18M ﹤0.01% 3047
2021
Q3 		$36.8M Buy
1,629,594
+687,316
+73% +$18.4M ﹤0.01% 2867
2021
Q2 		$24.3M Buy
942,278
+54,470
+6% +$1.68M ﹤0.01% 3184
2021
Q1 		$37M Buy
+887,808
New +$36M ﹤0.01% 2820

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's CGEM Position: Q2 2026 in Review

BlackRock increased its Cullinan Oncology (CGEM) stake by 18% in Q2 2026, buying an estimated $11.6M and bringing the position to 5,232,766 shares worth $95.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2252.

BlackRock first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • BlackRock held 5,232,766 shares of Cullinan Oncology worth $95.3M as of Q2 2026.
  • BlackRock bought 782,800 Cullinan Oncology shares in Q2 2026, an estimated $11.6M.
  • Cullinan Oncology made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2252 holding.
  • BlackRock first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.